HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in a variety of tumour cells through activation of TRAIL-R1 and TRAIL-R2 death signalling receptors. Here, we describe the characterisation and activity of HGS-ETR1, the first fully human, agonistic TRAIL-R1 mAb that is being developed as an antitumour therapeutic agent. HGS-ETR1 showed specific binding to TRAIL-R1 receptor. HGS-ETR1 reduced the viability of multiple types of tumour cells in vitro, and induced activation of caspase 8, Bid, caspase 9, caspase 3, and cleavage of PARP, indicating activation of TRAIL-R1 alone was sufficient to induce both extrinsic and intrinsic apoptotic pathways. Treatment of cell lines in vitro with HGS-ETR1 enhanced the cytotoxicity of chemotherapeutic agents (camptothecin, cisplatin, carboplatin, or 5-fluorouracil) even in tumour cell lines that were not sensitive to HGS-ETR1 alone. In vivo administration of HGS-ETR1 resulted in rapid tumour regression or repression of tumour growth in pre-established colon, non-small-cell lung, and renal tumours in xenograft models. Combination of HGS-ETR1 with chemotherapeutic agents (topotecan, 5-fluorouracil, and irinotecan) in three independent colon cancer xenograft models resulted in an enhanced antitumour efficacy compared to either agent alone. Pharmacokinetic studies in the mouse following intravenous injection showed that HGS-ETR1 serum concentrations were biphasic with a terminal half-life of 6.9-8.7 days and a steady-state volume of distribution of approximately 60 ml kg(-1). Clearance was 3.6-5.7 ml(-1) day(-1) kg(-1). These data suggest that HGS-ETR1 is a specific and potent antitumour agent with favourable pharmacokinetic characteristics and the potential to provide therapeutic benefit for a broad range of human malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, death receptor-targeted therapies (e.g., DR4/DR5 agonist antibodies) were shown to enhance the antitumor activity of chemotherapy drugs (5-FU, irinotecan) in CRC xenograft models [145,146,147].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries
Jostock, T., Vanhove, M., Brepoels, E., van Gool, R., Daukandt, M., Wehnert, A., van Hegelsom, R., Dransfield, D., Sexton, D., Devlin, M., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.03.014 · Cited by 2,572
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., & Winter, G. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90498-u · Cited by 1,603
Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., & Johnson, K. S. (1996) · Nature Biotechnology · doi:10.1038/nbt0396-309 · Cited by 1,027
Self-citationApo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Sprick, M. R., Weigand, M. A., Rieser, E., Rauch, C. T., Juo, P., Blenis, J., Krammer, P. H., & Walczak, H. (2000) · Immunity · doi:10.1016/s1074-7613(00)80211-3 · Cited by 794
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
Cited by
Items 201–300 of 305
Martin, B. P., Frew, A. J., Bots, M. L., Fox, S. B., Long, F., Takeda, K., Yagita∥, H., Atadja, P. W., Smyth, M. J., & Johnstone, R. W. (2010) · International Journal of Cancer · doi:10.1002/ijc.25594 · Cited by 14
Milutinovic, S., Kashyap, A. K., Yanagi, T., Wimer, C. D., Zhou, S., O’Neil, R. E., Kurtzman, A. L., Faynboym, A., Xu, L., Hannum, C. H., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0400 · Cited by 15
“As an alternative to TRAIL, highly specific agonistic antibodies targeting individual death receptors that avoid decoy receptor binding have been generated and developed as clinical therapeutics (4, 5).”
BackgroundResultGrund, K., Ahmadi, R., Jung, F., Funke, V., Gdynia, G., Benner, A., Sykora, J., Walczak, H., Joos, S., Felsberg, J., et al. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.12.6966 · Cited by 14
Finnberg, N. K., & El‐Deiry, W. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0567 · Cited by 15
Heijink, D. M., Jalving, M., Oosterhuis, D., Sloots, I. A., Koster, R., Hollema, H., Kleibeuker, J. H., Koornstra, J. J., de Vries, E. G. E., & de Jong, S. (2010) · The Journal of Pathology · doi:10.1002/path.2797 · Cited by 12
Pasello, G., Urso, L., Silic‐Benussi, M., Schiavon, M., Cavallari, I., Marulli, G., Nannini, N., Rea, F., Ciminale, V., & Favaretto, A. G. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000198 · Cited by 13
Kedinger, V., Muller, S., & Gronemeyer, H. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-34 · Cited by 14
“potent tumoricidal activity in cancer cells in vitro and in vivo, causing negligible effects on normal cells when exogenously administered, an important feature of this cascade regarding its therapeutic potential [9-25].”
BackgroundLi, Y., Wu, X., Jin, X., Wang, J., Togo, Y., Suzuki, T., Hashimoto, T., Yamada, Y., Nakanishi, Y., Kanematsu, A., et al. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000450 · Cited by 12
Sancilio, S., Grill, V., & Pietro, R. D. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208785294582 · Cited by 12
“Multiple solid tumours including lung, colon and renal carcinoma were found responsive to agonistic MoAbs treatment used alone or in combination with chemotherapy [131, 132].”
BackgroundManipulating the apoptotic pathway: potential therapeutics for cancer patients
Bates, D. J. P., & Lewis, L. D. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12193 · Cited by 12
Phage display for discovery of anticancer antibodies
Istomina, P. V., Gorchakov, A. A., Paoin, C., & Yamabhai, M. (2024) · New Biotechnology · doi:10.1016/j.nbt.2024.08.506 · Cited by 15
Recent Advances in the Application of Antibodies as Therapeutics
Burden, R. E., Caswell, J. M., Fay, F., & Scott, C. J. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.165 · Cited by 10
Affinity Maturation of Phage Display Antibody Populations Using Ribosome Display
Groves, M. A. T., & Nickson, A. A. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-379-0_10 · Cited by 11
Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas
Thomas, C. Y., & Theodorescu, D. (2006) · World Journal of Urology · doi:10.1007/s00345-006-0119-6 · Cited by 12
“Also, Bcl-2 inhibitors such as GX15-070 and AT-101 are in the early phases of clinical evaluation [136].”
BackgroundNovel Therapeutic Developments Other Than EGFR and VEGF Inhibition in Colorectal Cancer
Wilson, R. H. (2006) · The Oncologist · doi:10.1634/theoncologist.11-9-1018 · Cited by 10
FLIPping the Balance between Apoptosis and Proliferation in Thyroid Cancer
Mathew, R., & White, E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0620 · Cited by 11
Fabiano, A. R., Newman, M. W., Dombroski, J. A., Rowland, S. J., Knoblauch, S. V., Kusunose, J., Gibson-Corley, K. N., Kaufman, B. G., Ren, L., Caskey, C. F., et al. (2025) · Advanced Science · doi:10.1002/advs.202412995 · Cited by 13
Ding, B., Zhang, W., Wu, X., Wang, J., Xie, C., Huang, X., Zhan, S., Zheng, Y., Huang, Y., Xu, N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11014 · Cited by 10
“In early phase clinical trials, monoclonal antibodies targeting DR5 (DR5 mAb) have also been shown to increase the cytotoxicity of conventional chemotherapeutic drugs [24-26].”
BackgroundJin, A., Ozawa, T., Tajiri, K., Lin, Z., Obata, T., Ishida, I., Kishi, H., & Muraguchi, A. (2010) · European Journal of Immunology · doi:10.1002/eji.201040551 · Cited by 10
Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells
Ahmed, S. M. U., Wu, X., Jin, X., Zhang, X., Togo, Y., Suzuki, T., LI, Y., Kanematsu, A., NOJIMA, M., Yamamoto, S., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3654 · Cited by 10
Wang, L., Deng, R., Chen, S., Tian, R., Guo, M., Chen, Z., Zhang, Y., Li, H., Liu, Q., Tang, S., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06327-5 · Cited by 9
“HGS-ETR1 (mapatumumab) and HGS-ETR2 (lexatumumab) are humanized monoclonal antibodies developed by Human Genome Sciences (HGS) that speci fi cally bind to DR4/5 protein [9 – 11].”
Jin, X., Wu, X., Jin, C., Inui, M., Sugimoto, M., & Kakehi, Y. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32834fd796 · Cited by 9
Zhang, X., Frank, A. C., Gille, C. M., Daucher, M., Kabát, J., Becker, S., Lempicki, R. A., Cortez, K. J., Polis, M. A., Subramanian, G. M., et al. (2009) · Hepatology Research · doi:10.1111/j.1872-034x.2009.00568.x · Cited by 9
Targeting Death-Receptors in Radiation Therapy
Niemoeller, O. M., & Belka, C. (2009) · Results and problems in cell differentiation · doi:10.1007/400_2009_17 · Cited by 10
“Phase I and phase II clinical studies have shown low toxicity and some evidence of tumoricidal activity (Chow et al. 2006; Georgakis et al. 2005; Kanzler et al. 2005; Pacey et al. 2005; Pukac et al. 2005; Tolcher et al. 2007).”
BackgroundSecchiero, P., Sblattero, D., Chiaruttini, C., Melloni, E., Macor, P., Zorzet, S., Tripodo, C., Tedesco, F., Marzari, R., & Zauli, G. (2009) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200902200109 · Cited by 9
Walczak, H., Koschny, R., Willen, D., Schader, M. B., Sykora, J., Ganten, T. M., & Haas, T. L. (2006) · Wiley eBooks · doi:10.1002/9783527619665.ch2 · Cited by 10
Derby, L., & Czuczman, M. S. (2011) · Future Oncology · doi:10.2217/fon.11.79 · Cited by 8
Bao, Y., Wu, X., Kanematsu, A., Kita, Y., Kobayashi, T., Kakehi, Y., & Yamamoto, S. (2023) · Oncology Reports · doi:10.3892/or.2023.8671 · Cited by 8
Pharmacotherapy of large B-cell lymphoma
Escalón, M. P., & Lossos, I. S. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.13.2247 · Cited by 8
“These include proteasome inhibitors [61-64] , heat-shock protein inhibitors [65-68] , mammalian target of rapamycin (mTOR) inhibitors [69-72] , anti-tumor necrosis factor-related apoptosis-inducing ligand treatment (TRAIL) antibodies [73,74] , anti-VEGF antibodies [75-78] , anti-CD40 antibodies [79-82] , and histone d…”
BackgroundThe new paradigm in the treatment of colorectal cancer: are we hitting the right target?
Baranda, J. C., & Williamson, S. K. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.3.311 · Cited by 9
“Combining HGS-ETR1 with chemotherapeutic agents in three independent colon cancer xenograft models resulted in an enhanced antitumor efficacy compared with either agent alone [109].”
BackgroundPennarun, B., Kleibeuker, J. H., Oenema, T. A., Stegehuis, J. H., de Vries, E. G. E., & de Jong, S. (2010) · Analytical Cellular Pathology · doi:10.1155/2010/978097 · Cited by 12
Emerging apoptosis agonists for bladder cancer
Protzel, C., & Hakenberg, O. W. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903251708 · Cited by 7
“Mapatumumab was successfully tested as a single agent or in combination with chemotherapeutics in vitro and in colon cancer, NSCLC and kidney cancer xenograft models [59,60].”
BackgroundIdentification and characterization of a novel agonistic anti-DR4 human monoclonal antibody
Feng, Y., Xiao, X., Zhu, Z., & Dimitrov, D. S. (2010) · mAbs · doi:10.4161/mabs.2.5.12570 · Cited by 8
Novel treatment strategies for aggressive non-Hodgkin’s lymphoma
Fayad, L., & Younes, A. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.6.733 · Cited by 7
“Both anti-TRAIL-R1 and -R2 demonstrated activity against a wide variety of cultured and primary lymphoma cells in vitro [29,30].”
BackgroundFarooqi, A. A., Gadaleta, C. D., Ranieri, G., Fayyaz, S., & Marech, I. (2016) · Current Genomics · doi:10.2174/1389202917666160803150023 · Cited by 6
“In fact, not only recombinant human TRAIL (dulanermin), but also agonistic antibodies for TRAIL receptors have been developed as anti-cancer agents including TRAIL-R1 (mapatumumab) or TRAIL-R2 (conatumumab ,drozitumab , lexatumumab, LBY135 and tigatuzumab [10-15].”
BackgroundGoto, M., Owaki, K., Hirata, A., Yanai, T., & Sakai, H. (2019) · Veterinary and Comparative Oncology · doi:10.1111/vco.12471 · Cited by 6
Goldmacher, V. S., Gershteyn, I. M., & Kovtun, Y. (2024) · Antibody Therapeutics · doi:10.1093/abt/tbae029 · Cited by 6
“Mapatumumab, also known as HGS-ETR1 or TRM1 [31], is the only anti-DR4 monoclonal antibody that has been evaluated in clinical trials.”
Maira, S.-M., Pearson, M. A., Fabbro, D., & García-Echeverría, C. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00202-9 · Cited by 8
MADD promotes the survival of human lung adenocarcinoma cells by inhibiting apoptosis
Bi, W., Wei, Y., Wu, J., Sun, G., GUO, Y., Zhang, Q., & Dong, L. (2013) · Oncology Reports · doi:10.3892/or.2013.2258 · Cited by 5
“TRAIL is a promising candidate for cancer therapy as it can selectively induce apoptosis in tumor cells and effectively kill them but not normal cells (15).”
BackgroundThe Construction and Expression of a Novel Chimeric Anti-DR5 Antibody
Kunpeng, Z., Yugang, W., Jugao, C., Li, Y., Beifen, S., & Yuan-fang Ma, A. (2009) · Hybridoma · doi:10.1089/hyb.2008.0080 · Cited by 5
Emerging Non-transplant-based Strategies in Treating Pediatric Non-Hodgkin’s Lymphoma
Gore, L., & Trippett, T. M. (2010) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-010-0058-6 · Cited by 5
Pennarun, B., Kleibeuker, J. H., Oenema, T. A., Stegehuis, J. H., de Vries, E. G. E., & de Jong, S. (2011) · Cellular Oncology · doi:10.1007/s13402-011-0033-9 · Cited by 12
Monoclonal Antibodies: An Emerging Class of Therapeutics in Non Small Cell Lung Cancer
Guilleminault, L., Lemarié, É., & Heuzé‐Vourc'h, N. (2012) · Journal of Cancer Therapy · doi:10.4236/jct.2012.36153 · Cited by 4
“The tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), also known as Apo2L, is a member of the TNF ligand superfamily [173,174].”
BackgroundProteomic tools for the characterization of cell death mechanisms in drug discovery
Anania, V. G., & Lill, J. R. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400151 · Cited by 5
“Multiple approaches have been taken to target these receptors, including the development of molecules, such as recombinant soluble Apo2L/TRAIL (dulanermin) [3], monoclonal antibodies against DR5 (conatumumab, drozitumab, tigatuzumab, and lexatumumab) [4–8], and a fully humanized agonist antibody against DR4 (mapatumum…”
BackgroundClinical trials of promising apoptosis modulating drugs
Sharma, N., Kumari, R. M., Arya, G., Gupta, N., Chandra, R., & Nimesh, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815762-6.00010-x · Cited by 5
Drug target identification and quantitative proteomics
He, T., Kim, Y. J., Heidbrink, J. L., Moore, P. A., & Ruben, S. M. (2006) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.1.5.477 · Cited by 5
“Depending on their biological role, such candidates could serve as targets for a functional mAb that neutralises or activates a target-mediated biological pathway [44,45].”
BackgroundManipulating Cell Death in Cancer
Al-Janabi, I. I. (2025) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v9i1.2131 · Cited by 3
Guo, L., Sun, X., Hao, Z., Huang, J., Han, X., You, Y., Li, Y., Shen, M., Ozawa, T., Kishi, H., et al. (2017) · Journal of Cancer · doi:10.7150/jca.19918 · Cited by 4
“Thus, several mAbs targeting TRAIL-R1 or TRAIL-R2, which have antitumor activity, have been established as another therapeutic strategy instead of TRAIL [32-34] and have shown promising activity in preclinical observations [35].”
BackgroundDereli‐Korkut, Z., Gandhok, H., Zeng, L. G., Waqas, S., Jiang, X., & Wang, S. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24804 · Cited by 3
“Currently, TRAIL based therapies are under development using recombinant TRAIL or agonistic antibodies [e.g., Mapatumumab (Pukac et al., 2005)] for DR4 and DR5 to either enhance TRAIL toxicity (Sloot et al., 2006) or combine with chemotherapy and radiotherapy to sensitize tumor cells (Lashinger et al., 2005; Martin et…”
BackgroundMethodInfluentialWaerzeggers, Y., Monfared, P., Viel, T., Faust, A., Kopka, K., Schäfers, M. A., Tavitian, B., Winkeler, A., & Jacobs, A. H. (2011) · British Journal of Radiology · doi:10.1259/bjr/66405626 · Cited by 5
“Pre-treatment with tolerable doses of paclitaxel resulted in a striking, time-dependent upregulation of TRAIL-R1 and TRAIL-R2, as shown by in vivo tumour SPECT imaging using radiolabelled HGS-ETR1 and HGS-ETR2 and by analysis of steady-state protein levels from the colorectal tumour xenografts.”
BackgroundInfluentialTargeting Lymphoma Cells and Their Microenvironment with Novel Antibodies
Wedgwood, A., & Younes, A. (2006) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2006.s.006 · Cited by 3
Mechanistic role of pyroptosis in tumor microenvironment and tumor immunotherapy
Attar, R., Qureshi, M. Z., Sabitaliyevich, U. Y., Yulaevna, I. M., & Romero, M. A. (2024) · Cellular and Molecular Biology · doi:10.14715/cmb/2024.70.4.41 · Cited by 3
“These agonistic antibodies have been reported to be effective against different cancers (85-88).”
BackgroundApoptotic Cell Death: Important Cellular Process as Chemotherapeutic Target
Junaid, M., Akter, Y., Afrose, S. S., Tania, M., & Khan, M. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-7586-0_4 · Cited by 2
Signalling Pathways Leading to TRAIL Resistance
Di, R. (2011) · InTech eBooks · doi:10.5772/24903 · Cited by 2
“As well, multiple solid tumours including lung, colon and renal carcinoma were found responsive to TRAs treatment used alone or in combination with chemotherapy (Pukac et al., 2005).”
BackgroundHuang, Y., Liang, B., Jiang, Q. L., CHEN, C., Yang, K., LI, C., & Zheng, A. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2193 · Cited by 2
“Evidence of this principle has been reported with murine, rabbit or human agonistic DR5 antibodies, exhibiting a tumoricidal activity in vitro and in vivo (12).”
InfluentialThe Characteristic of an Anti-Human DR5 Antibody A6
Wang, Y.-G., Zhao, K., Chen, J.-G., Zhang, J., Yu, M., Li, Y., & Shen, B.-F. (2008) · Cellular and Molecular Immunology · doi:10.1038/cmi.2008.22 · Cited by 2
“In humans, TRAIL binds to two death-inducing receptors, DR4/TRAIL-R1 and DR5/TRAIL-R2/KILLER.”
BackgroundGoto, M., Hirata, A., Murakami, M., & Sakai, H. (2019) · Journal of Veterinary Medical Science · doi:10.1292/jvms.19-0469 · Cited by 2
“Several studies investigating the TRAIL pathway in HBC and other tumors have designed various TRAIL receptor-specific antibodies, and some antibodies are undergoing clinical trials [4, 5, 19, 26, 32, 43, 45].”
BackgroundKwon, Y., Lee, Y.-R., Kim, Y., Lee, H., & Jang, Y. (2007) · Oncology Reports · doi:10.3892/or.18.2.513 · Cited by 2
Ma, L., Zhang, J., Dai, Z., Liao, P., Guan, J., & Luo, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1512349 · Cited by 1
Molecular Pathogenesis of Urothelial Carcinoma and the Development of Novel Therapeutic Strategies
Thomas, C. Y., & Theodorescu, D. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-417-9_26 · Cited by 1
Juan, G., Zoog, S. J., & Ferbas, J. (2011) · Methods in cell biology · doi:10.1016/b978-0-12-374912-3.00012-2 · Cited by 3
“, 2010) or others (Adams et al., 2008;Chuntharapai et al., 2001;Georgakis et al., 2005;Guo et al., 2005; Ichikawa et al., 2001; Motoki et al., 2005; Pukac et al., 2005) can be used to bind and activate DR signaling.”
BackgroundBiological Therapy of Non-Hodgkin's Lymphomas
Zelenetz, A. D. (2006) · Elsevier eBooks · doi:10.1016/b978-0-7216-0081-9.50019-4 · Cited by 1
Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma
Ebadi, M., Reddy, N. M., & Rezaei, N. (2015) · Springer eBooks · doi:10.1007/978-3-662-46410-6_8 · Cited by 1
Thérapies ciblées et immunomodulation dans les tumeurs solides
Fayette, J., & Blay, J. (2006) · Réanimation · doi:10.1016/j.reaurg.2006.06.013 · Cited by 1
Lee, Y.-R., Hwang, E., & Jang, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081967 · Cited by 1
Kline, C. L. B., Wagner, J., Lulla, A. R., Ralff, M. D., Lev, A., Zhou, L., Prabhu, V. V., Stogniew, M., Schalop, L., Oster, W., et al. (2018) · Methods and principles in medicinal chemistry · doi:10.1002/9783527801756.ch23 · Cited by 1
Apoptosis Pathways and New Anticancer Agents
Kruyt, F. A. E., Rodríguez, J. A., & Giaccone, G. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-470-4_12
“In cell lines and mice models, these agents potently induced apoptosis [46, 47], and an enhanced antitumor activity was observed when combined with chemotherapy or radiation [48, 49].”
BackgroundNuevas terapias dirigidas para el tratamiento del cáncer
Heras, J. M. J., Yugueros, L. L., Maeso‐Alonso, L., Manuel, D. M., Gómez, L. M., Delgado, A. P., Manzano, C. P., García, I. P., Fuentes, P., Arias, P. P., et al. (2013) · Ambiociencias · doi:10.18002/ambioc.v0i9.5564
Antibodies in Phase I/II/III: Cancer Therapy
Deckert, P. M. (2007) · Wiley eBooks · doi:10.1002/9783527619740.ch25
Zhou, L. (2010) · ScholarlyCommons (University of Pennsylvania)
Hernandez‐Ilizaliturri, F. J., & Czuczman, M. S. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511781926.018
Immunopathology and Immunotherapy of Hodgkin Lymphoma
Ebadi, M., Zeng, Y., Gkotzamanidou, M. A., & Rezaei, N. (2015) · Springer eBooks · doi:10.1007/978-3-662-46410-6_7
2005 Highlights From: First Annual Lung Cancer Symposium, New York, NY, November 2005
D'Orazio, A. I., Reddy, G. K., Nadler, E., Gandara, D. R., & Jain, V. K. (2006) · Clinical Lung Cancer · doi:10.1016/s1525-7304(11)70686-6
Human Cancer Resistance to Trail-Apoptotic Pathway-Targeted Therapies
Bellail, A. C., & Hao, C. (2013) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-1-4614-7070-0_11
Mini-review TRAIL and cancer therapy
Kruyt, F. A. E. (2008)
Radioonkologie, A., Direktor, Ä., & BAMBERG, M. (2009)
Antikörpertherapie in klinischer und präklinischer Anwendung bei gastrointestinalen Karzinomen
Thalheimer, A., Brändlein, S., Vollmers, P., Thiede, A., Meyer, D., & Illert, B. (2007) · Der Onkologe · doi:10.1007/s00761-007-1190-3
“Die vielfältigen Kombinationstherapien mit Chemotherapeutika und monoklonalen Antikörpern machen die Behandlung von Patienten mit gastrointestinalen Karzinomen zwar deutlich komplexer als früher, bieten aber gerade Patienten mit Metastasen wesentlich effektivere Therapieansätze.”
BackgroundGordon, M. S. (2006) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)70261-6
Apoptose: to kill or not to kill.
Geboes, K., & Damme, N. V. (2011)
Best Practice & Research Clinical Haematology
van Meerten, T., & Hagenbeek, A. (2011)
Other Novel Targeted Therapies in Lung Cancer
Papadopoulos, K. P., & Tolcher, A. W. (2007) · CRC Press eBooks · doi:10.3109/9781420020359.007 · Cited by 1
Mechanisms of Tumor Cell Killing by Therapeutic Antibodies
Stewart, R. A., & Webster, C. I. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511596773.012
Defining a role for TRAIL in the regulation of the immune response to MCMV infection
Schuster, I. S. (2012) · UWA Profiles and Research Repository (UWA)
Jovicic, B. P., Raković, I., Petrović, S., Čanović, P. P., Petrović, D., Sekulic, S., Jovanović, I., & Jovicic, N. U. (2018) · Serbian Journal of Experimental and Clinical Research · doi:10.1515/sjecr-2017-0023
“Castleman’s disease, a rare lymphoproliferative disorder that is defined as a localized hyperplasia of the lymph follicles with or without germinative centers, with the existence of endothelial hyperplasia (31).”
BackgroundNew Monoclonal Antibodies for Indolent Non-Hodgkin Lymphoma
Robak, T. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5851-7_11
“components and DNA, and subsequent cell death [ 66 ] .”
BackgroundApoptosis, necroptosis, and pyroptosis in health and disease
Liao, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814208-0.00008-7 · Cited by 1
Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma
Ebadi, M., Sadeghi, M. A., Reddy, N. M., & Rezaei, N. (2020) · Springer eBooks · doi:10.1007/978-3-030-57949-4_7
(2006) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2006.07.051
Song, K., Benhaga, N., Anderson, R. L., & Khosravi‐Far, R. (2023) · doi:10.1158/0008-5472.c.6494385.v1
Song, K., Benhaga, N., Anderson, R. L., & Khosravi‐Far, R. (2023) · doi:10.1158/0008-5472.c.6494385
Sung, E.-S., Park, K.-J., Lee, S., Jang, Y.-S., Park, S.-K., Park, Y.-H., Kwag, W.-J., Kwon, M., & Kim, Y. (2023) · doi:10.1158/1535-7163.c.6531423.v1
Pavet, V., Beyrath, J., Pardin, C., Morizot, A., Lechner, M., Briand, J., Wendland, M., Maison, W., Fournel, S., Micheau, O., et al. (2023) · doi:10.1158/0008-5472.22384583
Sinha, A., Park, J. M., Gulzar, N., Pandya, D. N., Wadas, T. J., & Scott, J. K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.31.578303
Current and future prospective of caspases targeting in cancer therapy
Prabhu, D., Jain, S., Chawala, R., Jain, S., & Vaidya, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15644-1.00010-9 · Cited by 1
Research progress of TRAIL in cancer treatment
ZhiYun, Y. U., Kang, M., Ning, C., & Meng, X. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0165
“…[27] 、 Drozitumab ( PRO95780 ) [28] 、 Conatumumab ( AMG-655 ) [29] 、 LBY-135 [30] 和 Apomab [31] 。相较于 rhTRAIL (半衰期不超过 1 小时),这些单克隆抗体具有更长的半衰期,通常为数天至数周 [32] 。但遗憾的是,这些单克隆 抗体在多项癌症临床研究中未取得突破性疗效(表 1 ),其原因主要包括以下三方面 [24, 26] d 为克服第一代 TRAIL 治疗药物的局限性,研究人员探索了多种蛋白质修饰策略。通过在 rhTRAIL 蛋白的 N 端引入特定标签,如 Flag [41]…”
TRAIL signalling regulation by ezrin
Iessi, E. (2011) · theses.fr (ABES) · doi:10.70675/93da8855zf26dz4244z82a0zadae8f48c269
Metadata
- Authors
- Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., Carrell, J., Boyd, E., Yao, X. T., Zhang, L., Zhong, L., von Kerczek, A., Shepard, L., Vaughan, T., Edwards, B., Dobson, C., Salcedo, T., & Albert, V
- Affiliations
- Human Genome Sciences (United States) (US)
- Recombinant Antibody Technology (United Kingdom) (GB)
- Corresponding author
- Pukac, L
- Venue
- British Journal of Cancer
- Published
- 2005-04
- Volume
- 92
- Issue
- 8
- Pages
- 1430-1441
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2361994
- OpenAlex
- W1974144614
- Cited by
- 306
- References
- 56
- Citations by year
- 2025: 6 · 2024: 6 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 5 · 2019: 11 · 2018: 3 · 2017: 8 · 2016: 8 · 2015: 12 · 2014: 7 · 2013: 13 · 2012: 16
- FWCI
- 14.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- TRAIL-R1, TRAIL receptor 1, agonistic monoclonal antibody, TRAIL, apoptosis, caspase activation, PARP cleavage, combination chemotherapy, colon cancer, non-small cell lung cancer, renal tumours, xenograft models, pharmacokinetics, cancer therapy
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibody Specificity, Antineoplastic Agents, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Half-Life, Humans, Male, Mice, Nude, Neoplasms, Experimental, Blotting, Western, Apoptosis, Receptors, Tumor Necrosis Factor, Cell Line, Tumor, Mice, Receptors, TNF-Related Apoptosis-Inducing Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.